TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

NHS National Generic Pharmaceuticals Transition 2021_1

Pharmaceutical products
Various medicinal products
UK
Published value
Not published
Submission deadline Not published
Lots published4
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: The NHS Commissioning Board (operating under the name of NHS England): "NHS National Generic Pharmaceuticals Transition 2021_1". Published status: complete. Published value: Value not published. 4 published lots. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityThe NHS Commissioning Board (operating under the name of NHS England)Scope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: The NHS Commissioning Board (operating under the name of NHS England)
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for The NHS Commissioning Board (operating under the name of NHS England). These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
46Bids / Report
1.7% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 829 active published awards; 827 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityThe NHS Commissioning Board (operating under the name of NHS England)
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSFramework
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published29 Apr 2021, 13:43 BST
Last source update29 Apr 2021, 13:43 BST
Recurring procurementNot published
ClassificationPharmaceutical products, Various medicinal products
Delivery area
UK
OCIDocds-h6vhtk-02aba8
What is being bought
Transition and 33 % products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months).The total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months).
What changed
From the official release history
  1. Status changed to complete
    29 Apr 2021, 13:43 BST
  2. Official notice release published
    29 Apr 2021, 13:43 BST
  3. Buyer information updated
    29 Apr 2021, 13:43 BST
Lots and requirements (4)
Published by the contracting authority
  • Lot 1 · #01
    Transition 2021_1 - 100% Products (All regions)
    cancelled
    Published valueNot published
    NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). Additional information: Price is not the only award criterion and all criteria are stated only in the procurementdocuments
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 2 · #02
    Transition 2021_1 - CESW region (Transition & 33% products)
    cancelled
    Published valueNot published
    NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurementdocuments
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 3 · #03
    Transition 2021_1 - LSNE region (Transition & 33% products)
    cancelled
    Published valueNot published
    NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months)
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 4 · #04
    Transition 2021_1 - NWLN region (Transition & 33% products)
    cancelled
    Published valueNot published
    NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). Additional information: Price is not the only award criterion and all criteria are stated only in the procurementdocuments
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    29 Apr 2021, 13:43 BST
  2. Award active
    Not published · Not published
  3. Award active
    Not published · Not published
  4. Award active
    Not published · Not published
  5. Award active
    Not published · Not published
  6. Award active
    Not published · Not published
  7. Award active
    Not published · Not published
  8. Award active
    Not published · Not published
  9. Award active
    Not published · Not published
  10. Award active
    Not published · Not published
  11. Award active
    Not published · Not published
  12. Award active
    Not published · Not published
  13. Award active
    Not published · Not published
  14. Award active
    Not published · Not published
  15. Award active
    Not published · Not published
  16. Award active
    Not published · Not published
  17. Award active
    Not published · Not published
  18. Award active
    Not published · Not published
  19. Award active
    Not published · Not published
  20. Award active
    Not published · Not published
  21. Award active
    Not published · Not published
  22. Award active
    Not published · Not published
  23. Award active
    Not published · Not published
  24. Award active
    Not published · Not published
  25. Award active
    Not published · Not published
  26. Award active
    Not published · Not published
  27. Award active
    Not published · Not published
  28. Award active
    Not published · Not published
  29. Award active
    Not published · Not published
  30. Award active
    Not published · Not published
  31. Award active
    Not published · Not published
  32. Award active
    Not published · Not published
  33. Award active
    Not published · Not published
  34. Award active
    Not published · Not published
  35. Award active
    Not published · Not published
  36. Award active
    Not published · Not published
  37. Award active
    Not published · Not published
  38. Award active
    Not published · Not published
  39. Award active
    Not published · Not published
  40. Award active
    Not published · Not published
  41. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  42. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  43. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  44. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  45. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  46. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  47. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  48. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  49. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  50. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  51. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  52. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  53. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  54. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  55. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  56. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  57. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  58. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  59. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  60. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  61. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  62. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  63. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  64. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  65. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  66. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  67. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  68. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  69. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  70. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  71. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  72. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  73. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  74. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  75. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  76. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  77. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  78. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
  79. Contract active
    Signed 17 Mar 2021, 00:00 GMT · £1
Commercial outcome and competition
Awards
Ascend Laboratories UK Ltd
Not published · Not published · active
Kent Pharma Ltd
Not published · Not published · active
Aspire Pharma Limited
Not published · Not published · active
Day Lewis Medical Ltd
Not published · Not published · active
Morningside Pharmaeuticals
Not published · Not published · active
Pfizer Ltd
Not published · Not published · active
Teva UK Limited
Not published · Not published · active
Tillomed Laboratories ltd
Not published · Not published · active
Thornton and Ross Ltd
Not published · Not published · active
Accord-UK Ltd
Not published · Not published · active
medac Pharma LLP
Not published · Not published · active
Aspire Pharma Limited
Not published · Not published · active
Amarox Limited
Not published · Not published · active
Dr.Reddy's Laboratories (UK) Limited
Not published · Not published · active
Aspen Pharma Ireland Limited
Not published · Not published · active
Morningside Pharmaeuticals
Not published · Not published · active
Teva UK Limited
Not published · Not published · active
Kent Pharma Ltd
Not published · Not published · active
Panpharma UK Limited
Not published · Not published · active
Pfizer Ltd
Not published · Not published · active
Selective Supplies Ltd.
Not published · Not published · active
Accord-UK Ltd
Not published · Not published · active
Brown and Burk UK Ltd
Not published · Not published · active
Aspen Pharma Ireland Limited
Not published · Not published · active
medac Pharma LLP
Not published · Not published · active
Dr.Reddy's Laboratories (UK) Limited
Not published · Not published · active
Kent Pharma Ltd
Not published · Not published · active
Day Lewis Medical Ltd
Not published · Not published · active
Morningside Pharmaeuticals
Not published · Not published · active
Panpharma UK Limited
Not published · Not published · active
Pfizer Ltd
Not published · Not published · active
Ranbaxy UK
Not published · Not published · active
Teva UK Limited
Not published · Not published · active
Day Lewis Medical Ltd
Not published · Not published · active
Martindale Pharma
Not published · Not published · active
Panpharma UK Limited
Not published · Not published · active
Aventis Pharma ltd t/a Sanofi
Not published · Not published · active
medac Pharma LLP
Not published · Not published · active
Aspen Pharma Ireland Limited
Not published · Not published · active
Contracts
Transition 2021_1 - 100% Products (All regions)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - CESW region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - CESW region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - CESW region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - CESW region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - CESW region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - CESW region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - CESW region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - CESW region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - LSNE region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - LSNE region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - 100% Products (All regions)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - LSNE region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - LSNE region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - LSNE region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - LSNE region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - LSNE region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - LSNE region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - LSNE region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - LSNE region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - LSNE region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - NWLN region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - 100% Products (All regions)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - NWLN region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - NWLN region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - NWLN region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - NWLN region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - NWLN region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - NWLN region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - NWLN region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - NWLN region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - NWLN region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - NWLN region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - 100% Products (All regions)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - 100% Products (All regions)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - CESW region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - CESW region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - CESW region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Transition 2021_1 - CESW region (Transition & 33% products)
£1 · signed 17 Mar 2021, 00:00 GMT · active
Bid statistics
bids: 14 (lot 01)
bids: 14 (lot 01)
bids: 14 (lot 01)
bids: 14 (lot 01)
bids: 14 (lot 01)
electronicBids: 14 (lot 01)
electronicBids: 14 (lot 01)
electronicBids: 14 (lot 01)
electronicBids: 14 (lot 01)
electronicBids: 14 (lot 01)
foreignBidsFromEU: 14 (lot 01)
foreignBidsFromEU: 14 (lot 01)
foreignBidsFromEU: 14 (lot 01)
foreignBidsFromEU: 14 (lot 01)
foreignBidsFromEU: 14 (lot 01)
foreignBidsFromNonEU: 0 (lot 01)
foreignBidsFromNonEU: 0 (lot 01)
foreignBidsFromNonEU: 0 (lot 01)
foreignBidsFromNonEU: 0 (lot 01)
foreignBidsFromNonEU: 0 (lot 01)
smeBids: 7 (lot 01)
smeBids: 7 (lot 01)
smeBids: 7 (lot 01)
smeBids: 7 (lot 01)
smeBids: 7 (lot 01)
bids: 26 (lot 02)
bids: 26 (lot 02)
bids: 26 (lot 02)
bids: 26 (lot 02)
bids: 26 (lot 02)
bids: 26 (lot 02)
bids: 26 (lot 02)
bids: 26 (lot 02)
bids: 26 (lot 02)
bids: 26 (lot 02)
bids: 26 (lot 02)
bids: 26 (lot 02)
electronicBids: 26 (lot 02)
electronicBids: 26 (lot 02)
electronicBids: 26 (lot 02)
electronicBids: 26 (lot 02)
electronicBids: 26 (lot 02)
electronicBids: 26 (lot 02)
electronicBids: 26 (lot 02)
electronicBids: 26 (lot 02)
electronicBids: 26 (lot 02)
electronicBids: 26 (lot 02)
electronicBids: 26 (lot 02)
electronicBids: 26 (lot 02)
foreignBidsFromEU: 26 (lot 02)
Buyer and organisations in this procedure

The NHS Commissioning Board (operating under the name of NHS England)

Contracting authority GB-FTS-2505
View buyer profile

  • The NHS Commissioning Board (operating under the name of NHS England)
    buyer
    centralPurchasingBody

    2nd Floor, Rutland House, Runcorn, UK, WA7 2ES
    david.ford1@nhs.net

  • Accord-UK Ltd
    supplier

    Whiddon Valley, Barnstaple, UK, EX32 8NS

  • Amarox Limited
    supplier

    14 Lyon Road, Congress House, Harrow, UK, HA1 2EN

  • Ascend Laboratories UK Ltd
    supplier

    4th Floor, Cavendish House, 369 Burnt Oak Broadway, Edgware, UK, HA8 5AW

  • Aspen Pharma Ireland Limited
    supplier

    6 Bell Street, Maidenhead, UK, SL6 1BU

  • Aspire Pharma Limited
    supplier

    4 Rotherbrook Court, Bedford Road, Petersfield, UK, GU32 3QG

  • Aventis Pharma ltd t/a Sanofi
    supplier

    410 Thames Valley Park Drive, Reading, UK, RG6 1PT

  • Brown and Burk UK Ltd
    supplier

    6-9 The Square, Stockley Business Park, Uxbridge, UK, UB11 1FW

  • Day Lewis Medical Ltd
    supplier

    2 Peterwood Way, Croydon, UK, CR0 4UQ

  • Dr.Reddy's Laboratories (UK) Limited
    supplier

    6 Riverview Road, Beverley, UK, HU17 0LD

  • Kent Pharma Ltd
    supplier

    Joshna House, Crowbridge Rd, Orbital Park, Ashford, UK, TN24 0GR

  • Martindale Pharma
    supplier

    Building A2 Glory Park Avenue, Wooburn Green, High Wycombe, UK

  • Morningside Pharmaeuticals
    supplier

    5 Pavilion Way, Castle Business Park,, Loughborough, UK, LE11 5GW

  • Panpharma UK Limited
    supplier

    Cotton exchange, Bixteth street, Liverpool, UK, L3 9LQ

  • Pfizer Ltd
    supplier

    Walton Oaks, Dorking Road, Walton-on-the-Hill,, Tadworth, UK, KT20 7NS

  • Ranbaxy UK
    supplier

    5th Floor, Hyde Park11 Millington Road, Hayes, UK, UB3 4AZ

  • Selective Supplies Ltd.
    supplier

    25 Lucastes Lane, Haywards Heath, UK, RH16 1LE

  • Teva UK Limited
    supplier

    Ridings Point, Whistler Drive, Castleford, UK, WF10 5HX

  • The High Court
    reviewBody

    Strand, London, WC2A 2LL
    generaloffice@administrativecourtoffice.justice.gov.uk

  • Thornton and Ross Ltd
    supplier

    Manchester Road, Linthwaite, Huddersfield, UK, HD7 5QH

  • Tillomed Laboratories ltd
    supplier

    220 Butterfield, Great Marling, Luton, UK, LU2 8DL

  • medac Pharma LLP
    supplier

    Scion House, Stirling University Innovation Park, Sterling, UK, FK9 4NF
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published